Cinctive Capital Management LP Acquires New Position in Bicara Therapeutics Inc. $BCAX

Cinctive Capital Management LP acquired a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 41,849 shares of the company’s stock, valued at approximately $661,000. Cinctive Capital Management LP owned 0.08% of Bicara Therapeutics at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Cantor Fitzgerald L. P. purchased a new position in shares of Bicara Therapeutics during the third quarter worth approximately $1,579,000. Bank of America Corp DE boosted its holdings in shares of Bicara Therapeutics by 1.2% in the third quarter. Bank of America Corp DE now owns 456,621 shares of the company’s stock valued at $7,210,000 after purchasing an additional 5,393 shares during the period. Algert Global LLC bought a new position in Bicara Therapeutics in the third quarter worth approximately $278,000. Creative Planning bought a new stake in Bicara Therapeutics during the 3rd quarter valued at $159,000. Finally, Schonfeld Strategic Advisors LLC raised its position in Bicara Therapeutics by 91.8% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 504,085 shares of the company’s stock valued at $7,959,000 after purchasing an additional 241,334 shares in the last quarter.

Insider Buying and Selling

In other Bicara Therapeutics news, CFO Ivan Hyep sold 2,963 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $18.25, for a total value of $54,074.75. Following the completion of the transaction, the chief financial officer directly owned 145,355 shares in the company, valued at approximately $2,652,728.75. The trade was a 2.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Claire Mazumdar sold 36,766 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $19.17, for a total transaction of $704,804.22. Following the sale, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at approximately $6,506,144.64. The trade was a 9.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 101,269 shares of company stock worth $1,887,703 in the last three months.

Bicara Therapeutics Trading Up 1.1%

Shares of NASDAQ:BCAX opened at $19.40 on Tuesday. Bicara Therapeutics Inc. has a 12-month low of $7.80 and a 12-month high of $20.25. The business’s fifty day simple moving average is $16.84 and its 200-day simple moving average is $16.14. The company has a market capitalization of $1.06 billion, a PE ratio of -8.66 and a beta of -0.78.

Wall Street Analysts Forecast Growth

BCAX has been the topic of a number of recent research reports. Citizens Jmp began coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They set a “market perform” rating and a $31.00 price target on the stock. Citigroup initiated coverage on Bicara Therapeutics in a report on Thursday, January 29th. They issued an “outperform” rating for the company. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. Finally, UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $30.25.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.